Iris Van Alderwerelt Van Rosenburgh
DownloadHi-Res Photo
About
Titles
Graduate Student, Pharmacology
Biography
Iris studied Natural Sciences at the University of Cambridge (2014-2017) with a focus on Cancer Biology and Pharmacology. She is now a graduate student in the Politi and Lemmon laboratories at Yale, studying the mechanisms of sensitivity and resistance to EGFR targeted therapies in lung cancer. Outside of the lab, you can find her coaching the graduate crew to victory.
Education & Training
- BA
- University of Cambridge, Natural Sciences - Pharmacology (2017)
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Iris Van Alderwerelt Van Rosenburgh's published research.
Publications Timeline
A big-picture view of Iris Van Alderwerelt Van Rosenburgh's research output by year.
Mark A Lemmon, PhD, FRS
Anatoly Kiyatkin, PhD
Katerina Politi, PhD
Michael Grant, MD
Robert Homer, MD, PhD
Sarah Goldberg, MD, MPH
3Publications
113Citations
Publications
2022
Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations
van Alderwerelt van Rosenburgh I, Lu D, Grant M, Stayrook S, Phadke M, Walther Z, Goldberg S, Politi K, Lemmon M, Ashtekar K, Tsutsui Y. Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 19 mutations. Nature Communications 2022, 13: 6791. PMID: 36357385, PMCID: PMC9649653, DOI: 10.1038/s41467-022-34398-z.Peer-Reviewed Original ResearchCitationsAltmetric
2020
Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics
Kiyatkin A, van Alderwerelt van Rosenburgh IK, Klein DE, Lemmon MA. Kinetics of receptor tyrosine kinase activation define ERK signaling dynamics. Science Signaling 2020, 13 PMID: 32817373, PMCID: PMC7521189, DOI: 10.1126/scisignal.aaz5267.Peer-Reviewed Original ResearchCitationsAltmetricDrug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations
Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, Unni AM, Homer R, Lockwood WW, Michor F, Goldberg SB, Lemmon MA, Smith PD, Cross D, Politi K. Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations. Cancer Research 2020, 80: 2017-2030. PMID: 32193290, PMCID: PMC7392201, DOI: 10.1158/0008-5472.can-19-3819.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsOsimertinib resistancePreferred first-line therapyThird-generation EGFR tyrosine kinase inhibitorEGFR tyrosine kinase inhibitorsResistance EGFR mutationsFirst-line therapyMutant lung cancerFirst-line osimertinibSubsequent treatment approachesTransgenic mouse modelTyrosine kinase inhibitorsSecondary mutationsErlotinib treatmentLung cancerEGFR mutationsLung adenocarcinomaMouse modelTherapeutic strategiesTherapeutic testingTreatment approachesMutant tumorsResistance mutationsDrug sensitivityDriver mutationsKinase inhibitors
Academic Achievements and Community Involvement
honor Gruber Fellowship
Yale University AwardDetails08/23/2017United States